The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Myeloid Leukemia Treatment Market Research Report 2024
Synopsis
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Treatment market was valued at US$ 591.7 million in 2023 and is anticipated to reach US$ 1040.9 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Treatment.
Report Scope
The Acute Myeloid Leukemia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Myeloid Leukemia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Segment by Type
DC Regimen
AVD Regimen
VCD Regimen
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Acute myeloid leukemia is the second frequent type (after acute lymphocytic leukemia) of leukemia diagnosed in infants. About 15% of children from birth to 19 years of age diagnosed with leukemia have acute myeloid leukemia. The risk of acute myeloid leukemia is closely associated with age. About 90% of acute myeloid leukemia is diagnosed in middle age.
The global Acute Myeloid Leukemia Treatment market was valued at US$ 591.7 million in 2023 and is anticipated to reach US$ 1040.9 million by 2030, witnessing a CAGR of 7.9% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Acute Myeloid Leukemia Treatment, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Myeloid Leukemia Treatment.
Report Scope
The Acute Myeloid Leukemia Treatment market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Myeloid Leukemia Treatment market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Myeloid Leukemia Treatment companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Ambit Biosciences Corporation
Celgene Corporation
Cephalon
Clavis Pharma
Eisai
Genzyme Corporation
Sunesis Pharmaceuticals
Segment by Type
DC Regimen
AVD Regimen
VCD Regimen
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Myeloid Leukemia Treatment companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Myeloid Leukemia Treatment Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 DC Regimen
1.2.3 AVD Regimen
1.2.4 VCD Regimen
1.3 Market by Application
1.3.1 Global Acute Myeloid Leukemia Treatment Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Myeloid Leukemia Treatment Market Perspective (2019-2030)
2.2 Acute Myeloid Leukemia Treatment Growth Trends by Region
2.2.1 Global Acute Myeloid Leukemia Treatment Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acute Myeloid Leukemia Treatment Historic Market Size by Region (2019-2024)
2.2.3 Acute Myeloid Leukemia Treatment Forecasted Market Size by Region (2025-2030)
2.3 Acute Myeloid Leukemia Treatment Market Dynamics
2.3.1 Acute Myeloid Leukemia Treatment Industry Trends
2.3.2 Acute Myeloid Leukemia Treatment Market Drivers
2.3.3 Acute Myeloid Leukemia Treatment Market Challenges
2.3.4 Acute Myeloid Leukemia Treatment Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Myeloid Leukemia Treatment Players by Revenue
3.1.1 Global Top Acute Myeloid Leukemia Treatment Players by Revenue (2019-2024)
3.1.2 Global Acute Myeloid Leukemia Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Acute Myeloid Leukemia Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Myeloid Leukemia Treatment Revenue
3.4 Global Acute Myeloid Leukemia Treatment Market Concentration Ratio
3.4.1 Global Acute Myeloid Leukemia Treatment Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Myeloid Leukemia Treatment Revenue in 2023
3.5 Acute Myeloid Leukemia Treatment Key Players Head office and Area Served
3.6 Key Players Acute Myeloid Leukemia Treatment Product Solution and Service
3.7 Date of Enter into Acute Myeloid Leukemia Treatment Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Myeloid Leukemia Treatment Breakdown Data by Type
4.1 Global Acute Myeloid Leukemia Treatment Historic Market Size by Type (2019-2024)
4.2 Global Acute Myeloid Leukemia Treatment Forecasted Market Size by Type (2025-2030)
5 Acute Myeloid Leukemia Treatment Breakdown Data by Application
5.1 Global Acute Myeloid Leukemia Treatment Historic Market Size by Application (2019-2024)
5.2 Global Acute Myeloid Leukemia Treatment Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Acute Myeloid Leukemia Treatment Market Size (2019-2030)
6.2 North America Acute Myeloid Leukemia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acute Myeloid Leukemia Treatment Market Size by Country (2019-2024)
6.4 North America Acute Myeloid Leukemia Treatment Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Myeloid Leukemia Treatment Market Size (2019-2030)
7.2 Europe Acute Myeloid Leukemia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acute Myeloid Leukemia Treatment Market Size by Country (2019-2024)
7.4 Europe Acute Myeloid Leukemia Treatment Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size (2019-2030)
8.2 Asia-Pacific Acute Myeloid Leukemia Treatment Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size by Region (2019-2024)
8.4 Asia-Pacific Acute Myeloid Leukemia Treatment Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Myeloid Leukemia Treatment Market Size (2019-2030)
9.2 Latin America Acute Myeloid Leukemia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acute Myeloid Leukemia Treatment Market Size by Country (2019-2024)
9.4 Latin America Acute Myeloid Leukemia Treatment Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Myeloid Leukemia Treatment Market Size (2019-2030)
10.2 Middle East & Africa Acute Myeloid Leukemia Treatment Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acute Myeloid Leukemia Treatment Market Size by Country (2019-2024)
10.4 Middle East & Africa Acute Myeloid Leukemia Treatment Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Ambit Biosciences Corporation
11.1.1 Ambit Biosciences Corporation Company Detail
11.1.2 Ambit Biosciences Corporation Business Overview
11.1.3 Ambit Biosciences Corporation Acute Myeloid Leukemia Treatment Introduction
11.1.4 Ambit Biosciences Corporation Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.1.5 Ambit Biosciences Corporation Recent Development
11.2 Celgene Corporation
11.2.1 Celgene Corporation Company Detail
11.2.2 Celgene Corporation Business Overview
11.2.3 Celgene Corporation Acute Myeloid Leukemia Treatment Introduction
11.2.4 Celgene Corporation Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.2.5 Celgene Corporation Recent Development
11.3 Cephalon
11.3.1 Cephalon Company Detail
11.3.2 Cephalon Business Overview
11.3.3 Cephalon Acute Myeloid Leukemia Treatment Introduction
11.3.4 Cephalon Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.3.5 Cephalon Recent Development
11.4 Clavis Pharma
11.4.1 Clavis Pharma Company Detail
11.4.2 Clavis Pharma Business Overview
11.4.3 Clavis Pharma Acute Myeloid Leukemia Treatment Introduction
11.4.4 Clavis Pharma Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.4.5 Clavis Pharma Recent Development
11.5 Eisai
11.5.1 Eisai Company Detail
11.5.2 Eisai Business Overview
11.5.3 Eisai Acute Myeloid Leukemia Treatment Introduction
11.5.4 Eisai Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.5.5 Eisai Recent Development
11.6 Genzyme Corporation
11.6.1 Genzyme Corporation Company Detail
11.6.2 Genzyme Corporation Business Overview
11.6.3 Genzyme Corporation Acute Myeloid Leukemia Treatment Introduction
11.6.4 Genzyme Corporation Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.6.5 Genzyme Corporation Recent Development
11.7 Sunesis Pharmaceuticals
11.7.1 Sunesis Pharmaceuticals Company Detail
11.7.2 Sunesis Pharmaceuticals Business Overview
11.7.3 Sunesis Pharmaceuticals Acute Myeloid Leukemia Treatment Introduction
11.7.4 Sunesis Pharmaceuticals Revenue in Acute Myeloid Leukemia Treatment Business (2019-2024)
11.7.5 Sunesis Pharmaceuticals Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
